We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Current State of Systemic Therapy of Metastatic Uveal Melanoma.
- Authors
Koch, Elias A. T.; Heppt, Markus V.; Berking, Carola
- Abstract
Uveal melanoma (UM) is genetically a distinct tumor compared to cutaneous melanoma (CM), and due to its low mutational burden, it is far less perceptible to the immune system. Thus, treatments that have revolutionized the treatment of CM remain widely inefficient in metastatic UM or only demonstrate effectiveness in a small subpopulation of patients. To this end, the therapeutic benefit of immune checkpoint blockade is very limited and may come at the expense of severe immune-related adverse events that could potentially affect all organ systems. Notably, tebentafusp, an entirely novel class of anti-cancer drugs, has received official authorization for the treatment of metastatic UM. It is the first agent that demonstrated a survival advantage in a randomized controlled trial of metastatic UM patients. Despite the survival benefit and approval, the restriction of tebentafusp to HLA-A*02:01-positive patients and the low objective response rate indicate the persistent need for additional therapies. Thus, liver-directed therapies are commonly used for tumor control of hepatic metastases and represent a central pillar of the daily management of liver-dominant disease. Further, promising data from targeted therapies independent of MEK-inhibitors, such as the combination of darovasertib and crizotinib, raise hope for additional options in metastatic UM in the future. This narrative review provides a timely and comprehensive overview of the current treatment landscape for metastatic UM.
- Subjects
UVEA cancer; MELANOMA; DRUG side effects; T cells; ANTINEOPLASTIC agents; TREATMENT effectiveness; METASTASIS; MONOCLONAL antibodies; IMMUNE checkpoint inhibitors; TUMOR classification; IMMUNITY; OVERALL survival; CELL receptors; HLA-B27 antigen; GENOMES; PHARMACODYNAMICS
- Publication
American Journal of Clinical Dermatology, 2024, Vol 25, Issue 5, p691
- ISSN
1175-0561
- Publication type
Article
- DOI
10.1007/s40257-024-00872-1